The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer.
S. Modi
Research Funding - Infinity
C. Saura
No relevant relationships to disclose
C. A. Henderson
No relevant relationships to disclose
N. U. Lin
Research Funding - Boehringer Ingelheim; Genentech; GlaxoSmithKline
R. L. Mahtani
Honoraria - Genentech; Ortho Biotech
J. Goddard
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
E. Rodenas
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
J. O'Shaughnessy
No relevant relationships to disclose
J. Baselga
No relevant relationships to disclose